Report ID : 10042790 |
Published Date : 21 Mar 2025 |
Report Format : PDF,PPT |
Delivery Timeline :48-72 Business Hours
Uterine Fibroid Market Definition
Uterine fibroids are the most commonly occurring tumors in the female reproductive tract. These fibroids are also called uterine leiomyomas and they disrupt uterus functions by causing excessive bleeding, anemia, and pelvic discomfort. The exact cause of uterine fibroids is still unknown to the medical world. However, several risk factors like aging, race, vitamin D deficiency, and obesity have been identified. Endometrial ablation, hysterectomy, myomectomy, uterine artery embolization, radiofrequency ablation, and others are some treatment methods available for the healing and cure of uterine fibroids.
U.S. Uterine Fibroid Market: Key Insights
|
Base Year |
2022 |
|
Forecast Year |
2023-2033 |
|
CAGR |
~4% |
|
Base Year Market Size (2022) |
~ USD 237 Million |
|
Forecast Year Market Size (2033) |
~ USD 299 Million |
U.S. Uterine Fibroid Market Highlights Over 2023 - 2033
The U.S. uterine fibroid market is estimated to garner a revenue of ~ USD 299 Million by the end of 2033 by growing at a CAGR of ~4% over the forecast period, i.e., 2023 – 2033. Further, the market generated a revenue of ~ USD 237 Million in the year 2023. One of the major factors propelling the growth of the U.S. uterine fibroid market is the high prevalence of uterine fibroid among women in the United States (U.S.). The large presence of older women, obesity among women, vitamin D deficiency, and more contribute to a large number of fibroid cases among U.S. women. For instance, it is estimated that more than 25 million women in the U.S. between 15 and 50 have uterine fibroids.
GET A SAMPLE COPY OF THIS REPORT
Of these, ~16 million women are thought to experience symptoms and other concerns related to the health condition, including heavy menses, pain, anemia, reproductive issues, and increased urinary frequency. It was observed that in Florida alone, among women the ages 15-50 who suffered from uterine fibroid, the reproductive health condition was most common among non-Hispanic Black women (~46%).
U.S. Uterine Fibroid Market: Growth Drivers and Challenges
Growth Drivers
-
Availability of Pharmacologic Therapies to Alleviate the Symptoms – More than 70% of the women diagnosed with uterine fibroid had used pharmacologic therapy, including over-the-counter pain relief, prescription treatments, hormonal contraceptives, and iron supplements. Some of these medications treat fibroids by blocking reproductive hormones by temporarily mimicking a state similar to menopause by stopping menstruation and shrinking fibroids.
-
Improved Awareness of Women Regarding Uterine Fibroids – It was observed that ~50% of women who were considered at risk of uterine fibroids had some knowledge of the health condition.
-
High Investments in the Technological Development of Medical Devices – The total expenditure of the U.S. on medical devices is thought to surpass USD 159 billion in 2022.
Challenges
-
Deficiency of Non-surgical Treatment at Present – It is possible to destroy fibroids by cutting out the blood supply to them and forcing them to shrink and die through minimally invasive methods such as uterine artery embolization. However, fibroids can grow back, making the surgical removal of the uterus, the only cure for uterine fibroid.
-
Inadequate Health Insurance for the Surgical Procedures Related to Uterine Fibroid
-
High Cost Related to the Treatment Procedures Available Currently
The U.S. uterine fibroid market is segmented and analyzed for demand and supply by procedure type into endometrial ablation, MRI-guided procedures, hysterectomy, myomectomy, uterine artery embolization, radiofrequency ablation, and others. Of these, the hysterectomy segment is anticipated to hold the largest market size by the end of 2033. Hysterectomy treats fibroid-induced heavy periods, prolapse of the uterus, pelvic pain, and more, and thus becomes one of the most commonly performed surgical procedures on women worldwide. It is estimated that in the U.S., more than 599990 hysterectomy procedures are performed annually.
Market Segmentation
Our in-depth analysis of the U.S. uterine fibroid market includes the following segments:
|
By Procedure Type |
|
|
By End User |
|
Customize this Report: Request Customization
Key Companies Dominating the U.S. Uterine Fibroid Market
Our report has covered detailed company profiling comprising company overview, business strategies, key product offerings, financial performance, key performance indicators, risk analysis, recent developments, regional presence, and SWOT analysis among other notable indicators for competitive positioning. Some of the prominent industry leaders in the U.S. uterine fibroid market that are included in our report are BLUE ENDO, Boston Scientific Corporation (BSC), CooperSurgical, Inc., KARL STORZ SE & Co. KG, Myovant Sciences GmbH., Lina Medical ApS, Merit Medical Systems, Olympus Corporation of the Americas, Richard Wolf GmbH, Medtronic, and others.
U.S. Uterine Fibroid Market: Latest Developments
-
July 2021: Medtronic – announced the first gynecological (GYN) procedures employing the Hugo robotic-assisted surgery (RAS) system that enable less invasive surgical methods in the treatment of uterine fibroids and more.
-
May 2021: Myovant Sciences GmbH – announced the U.S. Food and Drug Administration (FDA) approval of MYFEMBREE, the first once-daily treatment to reduce heavy menstrual bleeding resulting from uterine fibroids in premenopausal women. Myovant had agreed to commercialize the product together with Pfizer.
